Stock Events

Stock Events

Acurx Pharmaceuticals 

€0.25
57
+€0+0% Monday 13:29

Statistics

Day High
0.26
Day Low
0.25
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-2.6
-1.78
-0.96
-0.15
Expected EPS
-1.2
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-13.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3ZO.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. is a global healthcare company that develops antibiotics and treatments for infectious diseases, directly competing with Acurx's focus on developing novel antibiotics.
Pfizer
PFE
Mkt Cap153.59B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products including antibiotics, making it a competitor in the infectious disease space.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline plc engages in the creation and discovery of pharmaceutical products, including antibiotics, competing in the same market as Acurx Pharmaceuticals.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie Inc. researches and develops a broad range of pharmaceuticals including treatments for infectious diseases, positioning it as a competitor.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson engages in the research and development of pharmaceuticals, including those for infectious diseases, making it a competitor in the healthcare sector.
Novartis
NVS
Mkt Cap280.79B
Novartis AG focuses on the discovery, development, and marketing of healthcare products, including antibiotics, which places it in competition with Acurx.
AMGEN
AMGN
Mkt Cap185.74B
Amgen Inc. is a biotechnology company that develops innovative human therapeutics, including treatments for infections, competing in the biopharmaceutical space.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol-Myers Squibb Company discovers, develops, and delivers innovative medicines, including those for infectious diseases, competing with Acurx's product pipeline.
Sanofi
SNY
Mkt Cap112.08B
Sanofi engages in the research, development, and marketing of pharmaceutical products, including antibiotics, making it a direct competitor.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca PLC is a global, science-led biopharmaceutical company that develops a range of pharmaceuticals, including those for bacterial infections, directly competing with Acurx Pharmaceuticals.

About

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Show more...
CEO
Mr. Robert J. DeLuccia
Employees
4
Country
United States
ISIN
US00510M1045
WKN
000A3CSCG

Listings

F
DE
3ZO0.F
XNAS
US
ACXP
STU
DE
3ZO0.STU
MU
DE
3ZO0.MU

0 Comments

Share your thoughts

FAQ

What is Acurx Pharmaceuticals stock price today?▼
The current price of 3ZO.F is €0.25 EUR — it has increased by +0% in the past 24 hours. Watch Acurx Pharmaceuticals stock price performance more closely on the chart.
What is Acurx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Acurx Pharmaceuticals stocks are traded under the ticker 3ZO.F.
What is Acurx Pharmaceuticals revenue for the last year?▼
Acurx Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is Acurx Pharmaceuticals net income for the last year?▼
3ZO.F net income for the last year is -13.12M EUR.
How many employees does Acurx Pharmaceuticals have?▼
As of April 29, 2026, the company has 4 employees.
In which sector is Acurx Pharmaceuticals located?▼
Acurx Pharmaceuticals operates in the Health & Wellness sector.
When did Acurx Pharmaceuticals complete a stock split?▼
Acurx Pharmaceuticals has not had any recent stock splits.
Where is Acurx Pharmaceuticals headquartered?▼
Acurx Pharmaceuticals is headquartered in Staten Island, United States.